Business Description
Modus Therapeutics Holding AB
ISIN : SE0015987904
Total Employee Number:
2Compare
Compare
Traded in other countries / regions
MODTX.Sweden99Z.Germany IPO Date
2021-07-30Description
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.39 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.86 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 13.1 | |||||
3-Year EPS without NRI Growth Rate | 12.6 | |||||
3-Year FCF Growth Rate | 18.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.01 | |||||
9-Day RSI | 25.12 | |||||
14-Day RSI | 32.81 | |||||
3-1 Month Momentum % | 59.3 | |||||
6-1 Month Momentum % | 75.64 | |||||
12-1 Month Momentum % | -37.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.88 | |||||
Quick Ratio | 3.88 | |||||
Cash Ratio | 3.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -43.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -432.3 | |||||
ROA % | -200 | |||||
ROIC % | -512.24 | |||||
3-Year ROIIC % | 1.25 | |||||
ROCE % | -425.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.77 | |||||
EV-to-EBIT | -2.59 | |||||
EV-to-Forward-EBIT | -0.84 | |||||
EV-to-EBITDA | -2.59 | |||||
EV-to-Forward-EBITDA | -0.84 | |||||
EV-to-FCF | -2.63 | |||||
Earnings Yield (Greenblatt) % | -38.61 | |||||
FCF Yield % | -33.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Modus Therapeutics Holding AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.02 | ||
| Beta | 3.2348 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.67 | ||
| Volatility % | 270.27 | ||
| 14-Day RSI | 32.81 | ||
| 14-Day ATR (€) | 0.001213 | ||
| 20-Day SMA (€) | 0.02747 | ||
| 12-1 Month Momentum % | -37.9 | ||
| 52-Week Range (€) | 0.0132 - 0.334 | ||
| Shares Outstanding (Mil) | 148.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Modus Therapeutics Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Modus Therapeutics Holding AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-24 | In 149 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 59 days | ||
| General meeting for 2026 | 2026-05-28 11:00 | 0.03 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-26 | 0.03 (+0.00%) | ||
| Annual report for 2025 | 2026-04-15 | 0.03 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 0.02 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-26 | 0.02 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 0.25 (+0.00%) | ||
| General meeting for 2025 | 2025-05-20 11:00 | 0.05 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 0.05 (+0.00%) |
Show
Entries
Modus Therapeutics Holding AB Frequently Asked Questions
What is Modus Therapeutics Holding AB(FRA:99Z)'s stock price today?
The current price of FRA:99Z is €0.02. The 52 week high of FRA:99Z is €0.33 and 52 week low is €0.01.
When is next earnings date of Modus Therapeutics Holding AB(FRA:99Z)?
The next earnings date of Modus Therapeutics Holding AB(FRA:99Z) is 2026-08-26.
Does Modus Therapeutics Holding AB(FRA:99Z) pay dividends? If so, how much?
Modus Therapeutics Holding AB(FRA:99Z) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Modus Therapeutics Holding AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers